Targeting CCL2 using its neutralizing antibody has been successful in mouse xenograft models in preventing prostate cancer metastasis [21,22]; however, it was reported that accelerated relapse and metastasis may occur once the antibody administration is interrupted [23]. Here, CCL2 is linked to prostate carcinoma.